1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
Viral Vector Manufacturing Market by Type, Disease, Application, End User - Global Forecast to 2023

Viral Vector Manufacturing Market: Global Forecast until 2023

  • August 2018
  • 149 pages
  • ID: 5484960
In this report:
The US is expected to account for the largest share of ##.##% of the North American viral vector manufacturing market in 2018, while Canada is expected to account for the remaining ##.##% of this market.
In 2018, the UK is expected to account for the largest share of ##.##% of the European viral vector manufacturing market, followed by Germany (##.##%), France (##.##%), and RoE (##.##%).

Summary

Table of Contents

Search Inside

The overall viral vector manufacturing market is estimated to rise at a compound annual growth rate of 20.00 percent.

The viral vector manufacturing market is forecasted to reach $815.80M by 2023 from an estimated $327.80M in 2018, at a compound annual growth rate (CAGR) of 20.00 percent. The increase of this market is anticipated to be driven by growing prevalence of target diseases and disorders, the availability of funding for gene therapy development, effectiveness of viral vectors in gene therapy delivery, and ongoing research into viral vector-based gene & cell therapies. On the other hand, the high cost of gene therapies and short shelf-life of viral vectors are likely to restrain the increase of this market to a certain extent.

The genetic disorders segment is anticipated to rise at the maximal rate during the outlook period

By disease, the viral vector manufacturing market is divided into cancer, genetic disorders, infectious diseases, and other diseases. During the estimate period, the genetic disorders segment is anticipated to grow at the highest compound annual growth rate (CAGR) due to the accelerated research activities on several genetic disorders including hemophilia A and B, sickle cell anemia, and Huntington's disease.

The pharmaceutical and biopharmaceutical firms to hold the largest market share

Established on end-user, the overall viral vector manufacturing market is broken down into pharmaceutical and biopharmaceutical firms and research institutes.The pharmaceutical and biopharmaceutical companies segment is forecasted to hold the biggest share of the market in 2018.

The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the top factors providing to the rise of the pharmaceutical and biopharmaceutical companies segment during the outlook period.

North America (NA) is forecasted to dominate the viral vector manufacturing market in 2018

In 2018, North America continent is forecasted to account for the biggest share of 64.80 percent of the overall viral vector manufacturing market. Elements such as a big number of regenerative medicine firms (including gene and cell therapy firms), growing research activities, increasing prevalence of target diseases, and availability of funding are supporting the increase of the viral vector manufacturing market in North America (NA).

Break of primary members taking part was as mentioned below:

• By Company category - Tier 1 - 40.0 percent, Tier 2 - 30.0 percent and Tier 3 - 30.0 percent

• By Description - C-suite - 20.0 percent, D-level - 40.0 percent, Others - 40.0 percent

• By Area - North America continent - 50.0 percent, Europe (EU) - 20.0 percent, Asia Pacific (APAC) - 20.0 percent, RoW - 10.0 percent

The main players in the overall viral vector manufacturing market are Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, uniQure, FUJIFILM Diosynth Biotechnologies, and Spark Therapeutics.

Segment Research

The market research examines the viral vector manufacturing market and aims at estimating the market value and upcoming growth potential of this market established on different aspects including type, disease, application, final user, and area. The industry report also comprises the competitive review of the main actors in this sector together with their company descriptions, product offerings, latest developments, and key industries strategies.

Reasons to Buy the Report

The study will facilitate established companies as well as new entrants/smaller companies gauge the pulse of the sector, which in turn, would benefit them collect a greater share of the market. Companies obtaining the analysis could use one or a combination of the below-mentioned strategies to enhance their rank in the industry.

This industry report offers business insights on these pointers:

• Market Uptake: Exhaustive data on product types provided by top players in the overall viral vector manufacturing market. The market research examines the overall viral vector manufacturing market by category, disease, application, end-user, and area

• Product Innovation: In-depth understanding on upcoming trends and launches of new product in the overall viral vector manufacturing market

• Market Development: Highlighted information about the profitable emerging sectors by category, disease, application, and end user

• industry diversification: Complete information about recent products, increasing geographies, recent evolutions, and market investments in the sector

• opposing assessment: Detailed assessment of market shares and increase strategies of leading actors in the overall market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Clinical Research in Von Hippel-Lindau Syndrome in H2, 2018

Clinical Research in Von Hippel-Lindau Syndrome in H2, 2018

  • $ 2500
  • September 2018

Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Von Hippel-Lindau Syndrome Global Clinical Trials Review, H2, 2018" provides an overview ...

Primary Immune Deficiency (PID) - Pipeline Review, H2 2018

Primary Immune Deficiency (PID) - Pipeline Review, H2 2018

  • $ 2000
  • August 2018

Primary Immune Deficiency (PID) - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, ...

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018SummaryAccording ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on